<head>
    <!-- Stylesheet -->
    <link rel="stylesheet" href="css/efficacy.css">
</head>
<!-- Main -->
<main>
    <div class="tabs">
        <a href="" ui-sref="ORR" class="tab">ORR</a>
        <a href="" ui-sref="TUMOR-VOLUME-ASSESSMENT" class="tab">TUMOR VOLUME ASSESSMENT</a>
        <a href="" ui-sref="DOR" class="tab tab--active">DoR</a>
    </div>
    <h2 class="primary">Durable Responses Occurred With BELEODAQ</h2>
    
    <h3 class="secondary-variant">Patients achieved a median TTR in fewer than 2 treatment cycles (n = 31)<sup>1,2</sup></h3>
    <div class="ttr">
        <h4>Median TTR was <span class="semibold">5.6</span> weeks<sup>1</sup></h4>
        <h4><span class="semibold">61%</span> (n = 19) achieved a response within <span class="semibold">4.3 to 6.4</span> weeks<sup>2</sup></h4>
        <h4>Response occurred up to <span class="semibold">50.4</span> weeks after the first dose<sup>1</sup></h4>
    </div>

    <h3 class="secondary-variant">DoR was calculated using 2 methods<sup>1,2</sup></h3>
    <ul>
        <li>
            <h4 class="light">
            Calculations for both methods began when a patient first met response criteria (CR or PR)
            </h4>
        </li>
    </ul>
    <h4 class="semibold">DoR as determined by SAP criteria was used by the FDA to evaluate durability and is included in the required labeling
    </h4>
    <div class="sap-criteria">
        <div class="sap-data">
            <span class="jumbo">8.4</span>
            <span>months<sup>1</sup></span>
            <p>(n = 31/95% CI, 4.5-29.4)</p>
        </div>
        <div class="sap-text">
            <h3>SAP criteria</h3>
            <h4>DoR measured from the first date of response to PD or death<br> 
            DoR definition of SAP differs from<br> 
            the more commonly used IWG definition</h4>
        </div>
    </div>
    <h4 class="semibold">DoR as determined by IWG criteria is a post-hoc analysis and is not included in the prescribing information</h4>
    <ul>
        <li>
            <h4 class="light">
            IWG criteria: DoR measured from the first date of response to subsequent date that relapse or progression was documented with patients who died censored at their last tumor assessment<sup>2</sup>
        </h4></li>
        <li class="sup lower"><h4 class="light">13.6 months<sup>1</sup> (n = 31/95% CI, 4.5-29.4)<sup>2</sup>
        </h4></li>
    </ul>
    <div class="cr2">
        <h3 class="secondary-variant">
            Responses were observed in patients who achieved a CR<sup>2</sup>
        </h3>
        <div class="cr2__data">
            <div class="data__left">
                <span class="jumbo">DoR >29</span>
                <span>months<sup>2</sup></span>
            </div>
            <div class="data__right">
                <h4>For those who achieved a CR (n = 13),</h4>
                <h4>median DoR was not only reached but exceeded<sup>1</sup></h4>
            </div>
        </div>
    </div>
    <h4 class="light"><span class="semibold">BELEODAQ is included in the NCCN<sup>&reg;</sup> Guidelines</span> as a Category 2A preferred second-line and subsequent therapy for <span class="semibold">PTCL-NOS; AITL; EATL; MEITL; nodal PTCL, TFH;</span> and <span class="semibold">FTCL</span>, <u>regardless of intention to proceed to transplant</u><sup>9</sup>
    </h4>
    <ul>
        <li class="lower"><h4 class="light">
            <span class="primary-variant semibold">7.5%</span> of patients proceeded to HSCT after treatment with BELEODAQ<sup>1</sup>
        </h4></li>
    </ul>
    <p class="light">AITL, angioimmunoblastic T-cell lymphoma; CR, complete response; DoR, duration of response; EATL; enteropathy-associated T-cell lymphoma; FTCL, follicular T-cell lymphoma; HSCT, hematopoietic stem cell transplant; IWG, International Working Group; MEITL, monomorphic epitheliotropic intestinal T-cell lymphoma; NCCN<sup>&reg;</sup>, National Comprehensive Cancer Network; PD, progressive disease; PR, partial response; SAP, statistical analysis plan; TFH, T follicular helper; TTR, time to response. </p>
    <div class="button-group">
        <a href="" ui-sref="INCLUSION-CRITERIA" class="button secondary"><i class="fas fa-chevron-left"></i>BELIEF Trial</a>
        <a href="" ui-sref="SAFETY" class="button">Safety &amp; Tolerability <i class="fas fa-chevron-right"></i></a>
    </div>
</main>